Insider Selling: Intellia Therapeutics (NASDAQ:NTLA) EVP Sells 8,508 Shares of Stock

by · The Markets Daily

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) EVP Birgit Schultes sold 8,508 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the sale, the executive vice president directly owned 98,533 shares in the company, valued at approximately $907,488.93. This trade represents a 7.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock traded up $0.40 during mid-day trading on Wednesday, reaching $10.13. The company’s stock had a trading volume of 5,058,443 shares, compared to its average volume of 4,466,384. The company has a market capitalization of $1.17 billion, a P/E ratio of -2.37 and a beta of 2.05. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $28.25. The firm’s fifty day moving average price is $9.58 and its two-hundred day moving average price is $12.70.

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.10. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The business had revenue of $13.78 million for the quarter, compared to analysts’ expectations of $14.12 million. During the same quarter in the prior year, the firm posted ($1.34) EPS. The firm’s quarterly revenue was up 51.6% on a year-over-year basis. On average, research analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of NTLA. CWM LLC lifted its stake in shares of Intellia Therapeutics by 4.7% in the 3rd quarter. CWM LLC now owns 19,187 shares of the company’s stock valued at $331,000 after acquiring an additional 856 shares during the last quarter. Federated Hermes Inc. increased its stake in Intellia Therapeutics by 39.7% in the 3rd quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock worth $56,000 after purchasing an additional 927 shares during the period. Cyndeo Wealth Partners LLC lifted its position in Intellia Therapeutics by 9.3% in the third quarter. Cyndeo Wealth Partners LLC now owns 11,710 shares of the company’s stock valued at $202,000 after purchasing an additional 995 shares during the last quarter. Interchange Capital Partners LLC boosted its stake in shares of Intellia Therapeutics by 9.7% during the third quarter. Interchange Capital Partners LLC now owns 11,695 shares of the company’s stock valued at $202,000 after purchasing an additional 1,030 shares during the period. Finally, Benjamin Edwards Inc. boosted its stake in shares of Intellia Therapeutics by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock valued at $591,000 after purchasing an additional 1,126 shares during the period. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on NTLA. Royal Bank Of Canada lowered their price objective on Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Friday, November 7th. Truist Financial reaffirmed a “buy” rating and issued a $14.00 price target (down previously from $25.00) on shares of Intellia Therapeutics in a report on Monday, November 10th. Bank of America cut their price objective on Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating for the company in a report on Monday, October 27th. JPMorgan Chase & Co. reaffirmed an “underweight” rating and issued a $5.00 target price (down from $12.00) on shares of Intellia Therapeutics in a research note on Friday, November 7th. Finally, Citigroup reissued a “market outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday, October 28th. Eleven analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Intellia Therapeutics has a consensus rating of “Hold” and an average target price of $18.43.

Get Our Latest Report on NTLA

About Intellia Therapeutics

(Get Free Report)

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.

Featured Stories